US Patent

US9180259 — Prefilled syringe jet injector

Formulation · Assigned to Antares Pharma Inc · Expires 2026-01-24 · 0y expired

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a jet injector that uses a prefilled syringe to deliver a medicament, such as testosterone enanthate, at a pressure of between 80 and 1000 p.s.i.

USPTO Abstract

A jet injector that includes a prefilled syringe. The syringe includes a fluid chamber that contains a medicament. The syringe also has an injection-assisting needle, and a plunger is movable within the fluid chamber. A housing is configured for allowing insertion of the needle to a penetration depth. An energy source is configured for biasing the plunger to produce an injecting pressure in the medicament in the fluid chamber of between about 80 and 1000 p.s.i. to jet inject the medicament from the fluid chamber through the needle to an injection site.

Drugs covered by this patent

Patent Metadata

Patent number
US9180259
Jurisdiction
US
Classification
Formulation
Expires
2026-01-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Antares Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.